Enhancing Written Information from the Pharmacy: An Update on MedGuides & Consumer Medicine Informat...
Download
1 / 16

Enhancing Written Information from the Pharmacy: An Update on MedGuides & Consumer Medicine Information (CMI) - PowerPoint PPT Presentation


Enhancing Written Information from the Pharmacy: An Update on MedGuides & Consumer Medicine Information (CMI). National Association of Chain Drug Stores 2006 Pharmacy & Technology Conference San Diego, CA July 28, 2006 William Ray Bullman Executive Vice President

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha

Download Presentation

Enhancing Written Information from the Pharmacy: An Update on MedGuides & Consumer Medicine Information (CMI)

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Slide1 l.jpg
Enhancing Written Information from the Pharmacy: An Update on MedGuides & Consumer Medicine Information (CMI)

National Association of Chain Drug Stores

2006 Pharmacy & Technology Conference

San Diego, CA

July 28, 2006

William Ray Bullman

Executive Vice President

National Council on Patient Information and Education

Bethesda, MD


Why so much emphasis on written prescription information l.jpg
Why so Much Emphasis on Written Prescription Information? on MedGuides & Consumer Medicine Information (CMI)

  • FDA regulation

  • High risk medications (e.g., Vioxx)

  • New IOM report – Preventing Medication Errors

  • CMI “usefulness” survey in 2007

  • Challenges with MedGuides

  • Many types of written prescription information


Fda regulation of prescription medicine information l.jpg
FDA Regulation of Prescription Medicine information on MedGuides & Consumer Medicine Information (CMI)

  • What the FDA regulates?

    • Professional labeling and promotional materials, including direct-to-consumer (DTC) advertising

  • What the FDA does NOT regulate

    • Websites with medication information

    • Consumer books (excluding some references)


Types of written information in pharmacies l.jpg
Types of Written Information in Pharmacies on MedGuides & Consumer Medicine Information (CMI)

  • Package Insert (PI)

  • Consumer Medicine Information (CMI)

  • Medication Guides (“MedGuides”)

  • Patient Information Sheets (PIS)

  • Patient Package Insert (PPI)


Package insert pi l.jpg
Package Insert (PI) on MedGuides & Consumer Medicine Information (CMI)

  • To gain marketing approval, manufacturers must have “official labeling” for its product approved by FDA. This includes both the label on container & “package insert” or “PI” which contains detailed information about indications, warnings, precautions, side effects, dosage, administration, and clinical pharmacology. PI also referred to as “professional labeling” because it is written primarily for physician & pharmacist.

  • With only a few exceptions, PI does NOT have to be given to patients because it is highly technical & not expected to be understood by average consumer. However, consumers can easily obtain PI via the PDR or by asking pharmacist or manufacturer for a copy.


An aside on pis l.jpg
An Aside on PIs on MedGuides & Consumer Medicine Information (CMI)

  • November 2005 -- FDA, in collaboration with National Library of Medicine (NLM) and NIH, launched “DailyMed, an interagency online health information clearinghouse.

  • “DailyMed” requires manufacturers to submit prescription drug label information to FDA in a new electronic format. This information can be accessed through the National Library of Medicine at http://dailymed.nlm.nih.gov

  • Currently includes 521 approved prescription drugs.


Medication guides medguides l.jpg
Medication Guides (MedGuides) on MedGuides & Consumer Medicine Information (CMI)

  • FDA has authority to require that FDA-approved labeling also include specific information for the patient under circumstances where the drug is considered to have significant safety issues that puts patient or public health at risk.

  • Under such a circumstance, FDA-approved written information for patients, called a “Medication Guide,” must be given to pt. when the drug is dispensed. For example, antidepressants & NSAIDs now require that an FDA-approved Medication Guide be dispensed with those prescription drugs.

  • MedGuides primarily emphasize “risks” as opposed to “benefits.”


Consumer medicine information cmi l.jpg
Consumer Medicine Information (CMI) on MedGuides & Consumer Medicine Information (CMI)

  • Unlike Europe, where patient information leaflets are highly regulated, only a few Rx drugs dispensed in the U.S. require FDA-approved written information for patients (primarily aforementioned Medication Guides).

  • Federal law (P.L. 104-180) in the U.S. requires that new Rxs be dispensed with written CMI). The law further requires that content & format of CMIs must be “useful” for patients, as defined by criteria developed by a multi-stakeholder committee – the Keystone Committee a decade ago.


Consumer medicine information cmi9 l.jpg
Consumer Medicine Information (CMI) on MedGuides & Consumer Medicine Information (CMI)

  • The content and format of each written consumer medication information sheet, i.e., a CMI leaflet, that is dispensed by a pharmacist with a prescription is usually developed by private companies. While these leaflets are based on FDA-approved labeling, their specific content and format are not subject to FDA approval.

  • However, FDA has authority to evaluate these pharmacist-delivered CMIs for “usefulness.” If the private sector fails to meet the goals of the Keystone Committee by 2006, the FDA has the authority to regulate the content and format of all future written information dispensed to patients with prescription drugs.


Patient information sheets pis l.jpg
Patient Information Sheets (PIS) on MedGuides & Consumer Medicine Information (CMI)

  • FDA in 2005 proposed a new Web page called “Drug Watch,” on which it would post emerging “safety alerts.”

    As part of this now revised initiative, the FDA links new safety alerts to what is called a “Patient Information Sheet” (PIS).

  • PIS are prepared by FDA and, like MedGuides, the focus of PIS is on risk information.

    For example of PIS for Gabitril  seewww.fda.gov/cder/drug/infopage/tiagabine/default.htm.


Patient information sheets pis11 l.jpg
Patient Information Sheets (PIS) on MedGuides & Consumer Medicine Information (CMI)

  • FDA has not disclosed plans for dissemination of its Patient Information Sheets. Currently, PIS exist solely on the FDA’s Web site and, unlike private sector CMI leaflets, PIS are not disseminated through community pharmacies.

  • Healthcare professionals are encouraged by FDA to download and provide PIS to consumers.


Patient package insert l.jpg
Patient Package Insert on MedGuides & Consumer Medicine Information (CMI)

  • For some prescription medicines, FDA approves manufacturer-prepared patient materials to instruct patients about the safe use of the product.

  • These materials may be given to patients by their health care provider or pharmacist.

  • Considered part of FDA-regulated product labeling.


Cmi where it stands august 2006 l.jpg
CMI – Where it Stands (August 2006) on MedGuides & Consumer Medicine Information (CMI)

  • 1996 Keystone Action Plan set 10-yr. timeframe for meeting specific target goals for formulation / dissemination of “Useful” CMI. FDA empowered to evaluate progress made by private sector:

    • By end of 2000: 75% of new Rxs convey with CMI that meets Action Plan criteria for content & design/layout and readability

    • By end of 2006: 95% of new Rxs convey with CMI that meets Action Plan criteria for content & design/layout and readability


Cmi where it stands august 200614 l.jpg
CMI – Where it Stands (August 2006) on MedGuides & Consumer Medicine Information (CMI)

  • FDA’s interim assessment (reported July ‘03) found:

    • CMI distribution @ 89% (> 75% target)

    • CMI content/quality @ 50% -55% (< 75% target)

  • Considerable concern voiced about how FDA contractor performed initial assessment (particularly by ASHP) & how final (’07) assessment will be conducted.


Cmi where it stands august 200615 l.jpg
CMI – Where it Stands (August 2006) on MedGuides & Consumer Medicine Information (CMI)

  • FDA released Final Guidance on Useful CMI July 17, 2006

  • FDA’s Final Guidance silent on how Agency will conduct final (2007) assessment, although likely it will be conducted like initial assessment (hidden shoppers; 4 Rxs; CMI collected & evaluated by panels of pharmacy experts & consumers)


What we know about the 2007 cmi assessment l.jpg
What We Know About the on MedGuides & Consumer Medicine Information (CMI)2007 CMI Assessment

  • FDA silent (but considering) expanding final assessment to include mail order CMI.

  • Action Plan will remain basis for FDA’s assessment; CMI Guidance will be used “to elucidate.”

  • Although encouraged to publish details about assessment for public comment (after collection of CMI in the field), FDA not excited about this approach.


ad
  • Login